BioSpace News Archive

Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones, including sitting without support

Forty Seven Inc. (NASDAQ:FTSV) today announced the formation of its Scientific Advisory Board (SAB), comprised of four leading scientists in the fields of immunotherapy and oncology.

CROP Infrastructure Corp., announces that further to its LOI with Naturally Splendid Enterprises (TSX-V: NSP)(OTCQB: NSPDF) (previously announced on August 14th 2018) CROP will utilize NSP’s proprietary HempOmega™ powder created from microencapsulated hemp seed oil in its ‘CannaDrink’ functional beverage line currently being developed.

The Rady Children’s Institute for Genomic Medicine (RCIGM) and IDbyDNA, a metagenomics technology company translating microbial genomics into actionable information for healthcare providers, have launched a clinical trial to improve diagnostics for pediatric central nervous system (CNS) infections.

Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company, today announced it has joined the Biotechnology Innovation Organization (BIO), the largest association of biotechnology companies, academic institutions and biotech centers around the world, and a leader in biotech innovation for over a quarter of a century.

TraceLink Inc. today announced that it now serves over 1,000 customers in 43 countries, delivering proven solutions for companies that are complying with U.S. Drug Supply Chain Security Act (DSCSA), EU Falsified Medicines Directive (FMD) and additional track and trace requirements in Russia, India, South Korea, China and Brazil.

Designation highlights serious unmet need for new treatment options for patients suffering from neuropathic pain

BrainStorm Cell Therapeutics Inc. announced today that members of its executive team will present at the Northeast Amyotrophic Lateral Sclerosis (NEALS) Conference in Clearwater, Florida and the Cell & Gene Meeting on the Mesa 2018 Conference in La Jolla, California, both taking place today, October 3, 2018.

Optinose today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS) 64th Annual Meeting in Atlanta, Georgia, October 5-6, 2018, and the American Academy Of Otolaryngology-Head and Neck Surgery Annual Meeting in Atlanta, Georgia, October 7-10, 2018.

Neon Therapeutics, Inc. will be presented in an upcoming oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19-23, 2018 in Munich, Germany.